logo
Volume 8, Issue 4 (Accepted and Pre-proof 2026)                   pbp 2026, 8(4): 0-0 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hrynovets I, Ostapchuk Y, Lysiuk R. Development and Pharmaceutical Characterization of an Oral Gel Containing Articaine and Aqueous Propolis Extract. , pbp. 2026; 8 (4)
URL: http://pbp.medilam.ac.ir/article-1-468-en.html
1- Danylo Halytsky Lviv National Medical University
2- Danylo Halytsky Lviv National Medical University , pharmacognosy.org.ua@ukr.net
Abstract:   (17 Views)
Introduction. Diseases and inflammatory conditions of the oral mucosa are often accompanied by pain, irritation, and disruption of tissue integrity. The development of topical oral dosage forms is challenging because the formulation is continuously exposed to saliva and mechanical clearance. A viscous dosage form capable of prolonging contact with the oral mucosa is therefore a relevant pharmaceutical objective.
Aim. To develop the composition and extemporaneous technology of an oral gel containing articaine (in the form of Artifrine) and aqueous propolis extract, and to experimentally characterize its physicochemical, rheological, analytical, mucoadhesive, and microbiological quality attributes.
Methods. The formulation contained Artifrine solution for injection (40 mg/mL articaine hydrochloride and 0.006 mg/mL epinephrine hydrochloride; ALC “Pharmaceutical Firm Darnytsia”, Ukraine), providing 0.2 g articaine hydrochloride per 100 g gel; aqueous propolis extract; sodium carboxymethylcellulose (Na-CMC); glycerol; propylene glycol; menthol; sodium saccharin; triclosan; and purified water. Na-CMC concentrations of 1.8–2.2% were evaluated, and 2.0% was selected. The gel was prepared using a seven-stage compounding process. Physicochemical, rheological, HPLC-UV, ex vivo mucoadhesive, microbiological, and preliminary stability assessments were performed.
Results. The optimized formulation contained Artifrine (5.0 mL), aqueous propolis extract (5.0 mL), Na-CMC (2.0 g), glycerol (8.0 g), propylene glycol (6.0 g), menthol (0.1 g), sodium saccharin (0.1 g), triclosan (0.2 g), and purified water to 100 g. The measured pH was 6.15 ± 0.08 and viscosity was 4850 ± 210 mPa·s at 20 rpm and 20 °C. Articaine content was 99.4 ± 1.2% of the target by HPLC-UV. Ex vivo detachment force was 0.42 ± 0.03 N. Microbiological testing after method-suitability neutralization met the stated limits. Preliminary three-month storage data at 25 °C/60% RH showed articaine and epinephrine contents of 98.1 ± 1.1% and 96.8 ± 1.4%, respectively.
Conclusions. An oral gel prototype containing articaine (as Artifrine) and aqueous propolis extract in a 2.0% Na-CMC matrix, together with a seven-stage extemporaneous manufacturing process, was developed and characterized. The results provide a basis for further pharmaceutical development. Long-term stability, drug-release, in vivo pharmacokinetic, and clinical studies remain necessary.


 
     
Type of Study: Research | Subject: Herbal Preparations
Received: 2026/10/11 | Accepted: 2026/11/11 | Published: 2026/09/6

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.